股本结构
单位：万股
| 公告日期 | 2023-08-14 | 2023-07-31 | 2023-07-14 | 2023-05-18 | 2023-05-01 | 2023-05-18 |
|---|---|---|---|---|---|---|
| 证券总股本 | 161.39 | 160.00 | 8069.35 | 8052.39 | 8048.52 | 8048.06 |
| 普通股本 | 161.39 | 160.00 | 8069.35 | 8052.39 | 8048.52 | 8048.06 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2023-08-08 | 2023-08-01 | 2023-07-10 | 2023-05-05 | 2023-04-07 | 2023-03-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2023-08-14 | 161.39 | 未披露 | 定期报告 | 2023-08-08 |
| 2023-07-31 | 160.00 | 未披露 |
更多>>
MedAvail Holdings, Inc. announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-50.
|
2023-08-01 |
| 2023-07-14 | 8069.35 | 未披露 | 定期报告 | 2023-07-10 |
| 2023-05-18 | 8052.39 | 未披露 | 定期报告 | 2023-05-05 |
| 2023-05-01 | 8048.52 | 未披露 | 定期报告 | 2023-04-07 |
| 2023-05-18 | 8048.06 | 未披露 |
更多>>
From March 31,2022 to March 31, 2023
Shares issued for vested RSUs
|
2023-03-31 |
| 2023-04-14 | 8116.97 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Shares issued for options exercises
Issuance of common shares with private placement
Shares issued for vested restricted stock units
Shares issued for ESPP
|
2022-12-31 |
| 2022-11-10 | 8004.57 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Issuance of common shares
Shares issued for vested restricted stock units
|
2022-09-30 |
| 2022-08-26 | 8199.24 | 未披露 | 定期报告 | 2022-07-31 |
| 2022-07-01 | 7996.77 | 未披露 | 定期报告 | 2022-07-01 |
| 2022-08-12 | 7061.00 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Issuance of common shares
Issuance of common shares under employee stock purchase plan
|
2022-06-30 |
| 2022-06-03 | 7055.60 | 未披露 | 定期报告 | 2022-04-08 |
| 2022-03-29 | 3290.89 | 未披露 | 定期报告 | 2022-03-24 |
| 2022-04-04 | 3290.20 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Exercise of warrants
Shares issued for options exercises
ESPP
|
2021-12-31 |
| 2021-11-09 | 3284.82 | 未披露 | 定期报告 | 2021-11-05 |
| 2021-11-09 | 3275.49 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Exercise of warrants
|
2021-09-30 |
| 2021-08-12 | 3274.65 | 未披露 | 定期报告 | 2021-08-10 |
| 2021-08-12 | 3258.37 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Shares issued for options exercises
Exercise of warrants
|
2021-06-30 |
| 2021-05-17 | 3252.08 | 未披露 | 定期报告 | 2021-05-14 |
| 2021-04-30 | 3194.58 | 未披露 | 定期报告 | 2021-04-29 |
| 2021-04-19 | 3194.48 | 未披露 | 定期报告 | 2021-04-16 |
| 2021-03-31 | 3193.99 | 未披露 | 定期报告 | 2021-03-29 |
| 2021-03-31 | 3181.60 | 未披露 |
更多>>
from December 31, 2019 to December 31, 2020
Shares issued in transaction
Issuance of preferred shares
Conversion of debt
Conversion of preferred shares
Issuance of common shares in connection with merger
Exercise of warrants
Shares issued for options exercises
Purchase of treasury stock
Issuance of treasury stock for options exercise
|
2020-12-31 |
| 2020-11-18 | 101.60 | 未披露 |
更多>>
Immediately following the Business Combination, there were approximately 31.7 million shares of Common Stock outstanding (post Reverse Stock Split). Immediately following the Business Combination Closing, the former MedAvail stockholders, warrant holders and option holders owned approximately 97.2% of the Company, with MYOS’s stockholders, warrantholders and option holders immediately prior to the Business Combination, whose warrants, options and shares of Common Stock remain outstanding after the Business Combination, owning approximately 2.8% of the Company.
|
2020-11-18 |
| 2020-10-09 | 1219.18 | 未披露 | 定期报告 | 2020-10-02 |
| 2020-08-04 | 1184.68 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Proceeds from sale of common stock, net
|
2020-06-30 |
| 2020-05-06 | 1103.01 | 未披露 |
更多>>
from December 31, 2019 to March 31, 2020
Proceeds from sale of common stock
Proceeds from private placement of common stock
Issuance of common stock upon exchange of related party promissory note payable
Issuance of restricted common stock
|
2020-03-31 |
| 2020-03-24 | 1085.74 | 未披露 | 定期报告 | 2020-03-24 |
| 2019-11-07 | 917.69 | 未披露 |
更多>>
from June 30, 2019 to September 30, 2019
Issuance of restricted common stock
|
2019-09-30 |
| 2019-08-06 | 917.07 | 未披露 | 定期报告 | 2019-06-30 |
| 2019-04-16 | 916.56 | 未披露 | 定期报告 | 2019-04-15 |
| 2019-05-08 | 917.07 | 未披露 |
更多>>
From December 31, 2018 to March 31, 2019
Net proceeds from sale of common stock
Net proceeds from private placement of stock
Issuance of common stock upon conversion of related party promissory note payable
Issuance of restricted stock
|
2019-03-31 |
| 2019-03-27 | 916.56 | 未披露 |
更多>>
Subsequent to year end on January 15, 2019, the Company sold 32,489 shares of common stock for $2.00 per share for gross proceeds of $65 in an at-the-market offering. On March 19, 2019 the Company sold 78,640 shares of common stock for $1.85 per share for gross proceeds of $145 in an at-the-market offering. As of the filing date of this Report, a total of 882,649 shares were sold under at-the market offerings for aggregate gross proceeds of $1,755.
|
2019-03-27 |
| 2019-03-27 | 748.17 | 未披露 |
更多>>
From December 31, 2017 to December 31, 2018
Proceeds from issuance of common stock, net
Shares issued to employees, directors and consultants
|
2018-12-31 |
| 2018-08-08 | 747.37 | 未披露 |
更多>>
From December 31, 2017 to June 27, 2018
Net proceeds from sale of common stock
Net proceeds from private sale of stock
Stock-based compensation expense
|
2018-06-27 |
| 2018-05-09 | 747.37 | 未披露 | 定期报告 | 2018-05-09 |
| 2018-04-18 | 665.82 | 未披露 | 定期报告 | 2018-04-17 |
| 2018-05-09 | 653.60 | 未披露 |
更多>>
From December 31, 2017 to March 31, 2018
Net proceeds from sale of common stock
Stock-based compensation expense
|
2018-03-31 |
| 2018-03-27 | 648.09 | 未披露 | 定期报告 | 2018-03-27 |
| 2018-03-27 | 634.06 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Proceeds from issuance of common stock, net
Shares forfeited by employees and directors
|
2017-12-31 |
| 2017-11-09 | 634.44 | 未披露 | 定期报告 | 2017-11-09 |
| 2017-05-12 | 584.44 | 未披露 |
更多>>
from December 31, 2016 to March 31, 2017
Net proceeds from sale of common stock
|
2017-03-31 |
| 2017-03-31 | 584.44 | 未披露 | 定期报告 | 2017-03-30 |
| 2017-03-31 | 534.44 | 未披露 |
更多>>
From December 31, 2015 to December 31, 2016
Proceeds from issuance of common stock, net
Shares issued to Board of Directors for services
Shares issued upon conversion of convertible note
|
2016-12-31 |
| 2016-11-14 | 508.61 | 未披露 |
更多>>
from December 31, 2015 to September 30, 2016
Private placement, net
Stock-based compensation expense
|
2016-09-30 |
| 2016-08-12 | 508.11 | 未披露 |
更多>>
from December 31, 2015 to June 30, 2016
Private placement, net
Stock-based compensation expense
|
2016-06-30 |
| 2016-05-13 | 508.11 | 未披露 | 定期报告 | 2016-05-12 |
| 2016-05-13 | 505.29 | 未披露 |
更多>>
from December 31, 2015 to March 31, 2016
Private placement, net
|
2016-03-31 |
| 2016-03-30 | 505.29 | 未披露 |
更多>>
On March 3, 2016, we completed the first tranche of the Financing pursuant to which the Purchaser acquired 1,500,000 shares of common stock and a warrant to purchase 375,000 shares of the Company’s common stock for $5.25 million.
|
2016-03-24 |
| 2016-03-30 | 355.29 | 未披露 |
更多>>
from December 31, 2014 to December 31, 2015
Issuance of common stock under Make-Whole Provisions
Exercise of Series D Warrants, net of issuance costs of $85
Shares issued to officers
Shares issued for services
Forfeiture of shares issued for services
|
2015-12-31 |
| 2015-11-16 | 332.29 | 未披露 | 定期报告 | 2015-11-12 |
| 2015-05-14 | 311.23 | 未披露 | 定期报告 | 2015-05-14 |
| 2014-08-14 | 290.94 | 未披露 | 定期报告 | 2014-08-13 |
| 2014-03-31 | 291.92 | 未披露 | 定期报告 | 2014-03-26 |
MedAvail Holdings, Inc. announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-50.
From March 31,2022 to March 31, 2023
Shares issued for vested RSUs
From December 31, 2021 to December 31, 2022
Shares issued for options exercises
Issuance of common shares with private placement
Shares issued for vested restricted stock units
Shares issued for ESPP
From June 30, 2022 to September 30, 2022
Issuance of common shares
Shares issued for vested restricted stock units
From March 31, 2022 to June 30, 2022
Issuance of common shares
Issuance of common shares under employee stock purchase plan
From December 31, 2020 to December 31, 2021
Exercise of warrants
Shares issued for options exercises
ESPP
From June 30, 2021 to September 30, 2021
Exercise of warrants
From March 31, 2021 to June 30, 2021
Shares issued for options exercises
Exercise of warrants
from December 31, 2019 to December 31, 2020
Shares issued in transaction
Issuance of preferred shares
Conversion of debt
Conversion of preferred shares
Issuance of common shares in connection with merger
Exercise of warrants
Shares issued for options exercises
Purchase of treasury stock
Issuance of treasury stock for options exercise
Immediately following the Business Combination, there were approximately 31.7 million shares of Common Stock outstanding (post Reverse Stock Split). Immediately following the Business Combination Closing, the former MedAvail stockholders, warrant holders and option holders owned approximately 97.2% of the Company, with MYOS’s stockholders, warrantholders and option holders immediately prior to the Business Combination, whose warrants, options and shares of Common Stock remain outstanding after the Business Combination, owning approximately 2.8% of the Company.
From March 31, 2020 to June 30, 2020
Proceeds from sale of common stock, net
from December 31, 2019 to March 31, 2020
Proceeds from sale of common stock
Proceeds from private placement of common stock
Issuance of common stock upon exchange of related party promissory note payable
Issuance of restricted common stock
from June 30, 2019 to September 30, 2019
Issuance of restricted common stock
From December 31, 2018 to March 31, 2019
Net proceeds from sale of common stock
Net proceeds from private placement of stock
Issuance of common stock upon conversion of related party promissory note payable
Issuance of restricted stock
Subsequent to year end on January 15, 2019, the Company sold 32,489 shares of common stock for $2.00 per share for gross proceeds of $65 in an at-the-market offering. On March 19, 2019 the Company sold 78,640 shares of common stock for $1.85 per share for gross proceeds of $145 in an at-the-market offering. As of the filing date of this Report, a total of 882,649 shares were sold under at-the market offerings for aggregate gross proceeds of $1,755.
From December 31, 2017 to December 31, 2018
Proceeds from issuance of common stock, net
Shares issued to employees, directors and consultants
From December 31, 2017 to June 27, 2018
Net proceeds from sale of common stock
Net proceeds from private sale of stock
Stock-based compensation expense
From December 31, 2017 to March 31, 2018
Net proceeds from sale of common stock
Stock-based compensation expense
from December 31, 2016 to December 31, 2017
Proceeds from issuance of common stock, net
Shares forfeited by employees and directors
from December 31, 2016 to March 31, 2017
Net proceeds from sale of common stock
From December 31, 2015 to December 31, 2016
Proceeds from issuance of common stock, net
Shares issued to Board of Directors for services
Shares issued upon conversion of convertible note
from December 31, 2015 to September 30, 2016
Private placement, net
Stock-based compensation expense
from December 31, 2015 to June 30, 2016
Private placement, net
Stock-based compensation expense
from December 31, 2015 to March 31, 2016
Private placement, net
On March 3, 2016, we completed the first tranche of the Financing pursuant to which the Purchaser acquired 1,500,000 shares of common stock and a warrant to purchase 375,000 shares of the Company’s common stock for $5.25 million.
from December 31, 2014 to December 31, 2015
Issuance of common stock under Make-Whole Provisions
Exercise of Series D Warrants, net of issuance costs of $85
Shares issued to officers
Shares issued for services
Forfeiture of shares issued for services